* Japanese*
American Association for Cancer Research
International Association for the Study of Lung Cancer
American Society of Clinical Oncology
English: Kodai Kawamura, et al, A randomized phase II study of 5-aminolevulinic acid hydrochloride and sodium ferrous citrate for the prevention of nephrotoxicity induced by cisplatin-based chemotherapy of lung cancer , Oncology , 2022
English: 3. Yoshida N., Okumura S., Sasaki T., Chiba S.-i., Sado M., Oyama K., Yoshida R., Hirai N., Minami Y., and Kitada M, SETD2 and miR-21 as therapeutic targets for NUT midline carcinoma , Journal of Cancer Science and Clinical Therapeutics , 2022
English: 2. Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, and Isobe H,, First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) , Sci Rep . , 2021
English: 1. Hirai N, Hatanaka Y, Hatanaka KC, Uno Y, Chiba SI, Umekage Y, Minami Y, Okumura S, Ohsaki Y, Sasaki T., Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer , Transl Lung Cancer Res . , 2021
English: Kosaka A., Yajima Y., Hatayama M., Ikuta K., Sasaki T., Hirai N., Yasuda S., Nagata M., Hayashi R., Harabuchi S., Ohara K., Ohara M., Kumai T., Ishibashi K., Hirata-Nozaki Y., Nagato T., Oikawa K., Harabuchi Y., Celis E., Okumura T., Ohsaki Y., Kobayashi H., and Ohkuri T., A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy , Cancer Science , 2021
Updated on 2022/11/24
Copyright (C) 2012～ Asahikawa Medical University, All Rights Reserved.
